biostudies-literatureUnknown47(4)Wittlieb-Weber CAThis study seeks to understand cardiac medication use in a large cohort of males with Duchenne Muscular Dystrophy (DMD) followed prospectively with focus on current practices and adherence to consensus directed medical therapy (CDMT). DMD patients have been enrolled in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry since 2021. Cardiac medication use was analyzed at enrollment and most recent follow-up. CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA). Two hundred sixty-five males with DMD (median age 17.5 (IQR 14.5-21.5) years) were prospectively folloPediatric cardiology1439-1450https://www.ebi.ac.uk/biostudies/studies/S-EPMC12945980biostudies-literatureCardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy.PMC12945980Gambetta KEHayes EAParent JJConway JWittlieb-Weber CAShugh SLal AKShih RWisotzkey BLRaucci FNandi DLorts ASoares NCunningham TWSoslow JHVilla CREsteso PHsu DTWilkens SJCastleberry CDMokshagundam DKaufman BDMartinez HBirnbaum BFKroslowitz BfalseCardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy.This study seeks to understand cardiac medication use in a large cohort of males with Duchenne Muscular Dystrophy (DMD) followed prospectively with focus on current practices and adherence to consensus directed medical therapy (CDMT). DMD patients have been enrolled in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry since 2021. Cardiac medication use was analyzed at enrollment and most recent follow-up. CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA). Two hundred sixty-five males with DMD (median age 17.5 (IQR 14.5-21.5) years) were prospectively follo2026-01-01T00:00:00Z2026 Apr2026-07-16T22:25:59.614Z2026-07-11T03:12:12.46ZS-EPMC129459804054001710.1007/s00246-025-03917-2